Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy

Table 2 Biochemical, pathological and virological parameters in HBV/HCV dually infected and HCV mono-infected patients

	Occult HBV/HCV Dual Infection (n = 6)		HCV Monoinfection (n = 149)		Test	P
Age (years)					t Test
X^- ± SD	32.8 ± 6.3		42.2 ± 9.1		2.48	0.013*
Range	20 - 36		19 - 59
Sex	No.	%	No.	%	X ²
M	6	100.0	119	79.9	0.49	0.48
F	0	0.0	30	20.1
BMI					t Test
X^- ± SD	25.7 ± 1.5		27.3 ± 3.6		1.1	0.27
Range	24 - 27.5		21 - 40.5
Basal ALT (× ULN)	No.	%	No.	%	X ²
≤2	6	100.0	112	75.2	0.83	0.36
> 2	0	0.0	37	24.8
Basal AST (× ULN)	No.	%	No.	%	X ²
≤2	4	66.7	122	81.9	0.16	0.68
> 2	2	33.3	27	18.1
Activity	No.	%	No.	%	X ²
1	2	33.3	50	33.6	1.88	0.39
2	4	66.7	67	44.9
3	0	0.0	32	21.5
Fibrosis	No.	%	No.	%	X ²
1	0	0.0	54	36.2
2	6	100.0	55	36.9	9.62	0.02*
3	0	0.0	36	24.2
4	0	0.0	4	2.7
Basal HCV Viral Load (IU × 10⁵)					t Test
X^- ± SD	10.05 ± 9.93		3.62 ± 5.4		2.74	0.006*
Range	0.4 - 22.3		0.001 - 22
Anti-HBc	No.	%	No.	%	X ²
Negative	4	66.7	133	89.3	1.09	0.29
Positive	2	33.3	16	10.7
Anti-HBs	No.	%	No.	%	X ²
Negative	6	100.0	131	87.9	0.07	0.79
Positive	0	0.0	18	12.1
Response Rate	No.	%	No.	%	X ²
Responder	0.0	0.0	70	46.98	3.42	0.06
Non-responder	6.0	100	79	53.02

ISSN: 1743-422X